Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Scientists have discovered novel drug candidates which could ultimately lead to new effective treatments for conditions ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today annou ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA ...

Cobenfy, a key component in BMS’ plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback in schizophrenia.

Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups.

Cobenfy (xanomeline/trospium chloride) is a prescription oral capsule that treats schizophrenia in adults. Learn about dosage, side effects, and more.

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.